Skye Bioscience Inc (SKYE) Directors and Executive Officers - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Skye Bioscience Inc   (NASDAQ: SKYE)

Skye Bioscience Inc

Officers & Directors


Kaitlyn Arsenault - Its

Punit Dhillon - Its

Margaret Dalesandro -

Deborah Charych -

Paul Grayson -

Andrew Schwab -

Annalisa Jenkins -

Keith Ward -

Praveen Tyle -

Marcum LLP - We have served as the - Company,

Skye Bioscience Inc currently has 12 employees.

  News about Skye Bioscience Inc Key Personnel

Skye Bioscience: Navigating the Road Ahead with Phase 2 Data and Market Challenges

Skye Bioscience Inc. a trailblazer in the innovative realm of cannabinoid-based therapeutics, is gearing up for a significant year in 2025. As the company looks to unveil important Phase 2 clinical trial data related to its unique CB1 inhibitor for obesity, industry watchers are paying close attention. The anticipated results, expected in the second and fourth quarters of 2025, could serve as a critical inflection point not just for Skye but for the broader landscape of obesity treatments.In recent months, however, Skye s fiscal landscape has been less rosy. Over the past five trading days, shares of Skye Bioscience plummeted by 15.16%. This downturn is compounded by a staggering cumulative net loss of $42 m...

Skye Bioscience Appoints Dr. Puneet S. Arora as CMO to Navigate Financial Turbulence and Pave the Way for Metabolic Health Breakthroughs,


By
City, - Skye Bioscience, a clinical-stage biopharmaceutical company dedicated to uncovering innovative therapeutic avenues for metabolic health, has recently announced the appointment of Dr. Puneet S. Arora as its new Chief Medical Officer (CMO). This strategic move comes at a crucial time for Skye Bioscience, which has been grappling with significant financial setbacks as revealed in its recent financial report.
According to Skye Bioscience s press release, Dr. Arora brings a wealth of experience and expertise to the company. With an impressive background in the healthcare sector, Dr. Arora holds an MD, MS, and FACE designation, making him a valuable addition to the executive leadership t...

Skye Bioscience Unites Top Experts in the Fight Against Obesity with the Formation of a Metabolic Clinical Advisory Board

Renowned Clinicians and Academics Join Skye Bioscience s Metabolic Clinical and Scientific Advisory Board to Drive the Development of Nimacimab
Skye Bioscience, a biopharmaceutical company focused on advancing innovative solutions in metabolic diseases, has recently established a Metabolic Clinical and Scientific Advisory Board. This esteemed board comprises renowned clinicians and academics with extensive experience in obesity and metabolic medicine. The board s main objective is to support the development of Skye Bioscience s promising drug candidate, Nimacimab.
Nimacimab is a groundbreaking therapeutic agent being developed by Skye Bioscience. It is designed to address the complex metabolic abnorm...






SKYE Management Effectiveness SKYE Revenue per Employee SKYE Income per Employee


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.